Feasibility and safety of PIPAC combined with additional surgical procedures: PLUS study.

[1]  A. Nissan,et al.  Consensus guidelines for pressurized intraperitoneal aerosol chemotherapy: Technical aspects and treatment protocols. , 2021, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[2]  J. Funder,et al.  The impact of postoperative complications following cytoreductive surgery combined with oxaliplatin based heated intraperitoneal chemotherapy. , 2021, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[3]  R. Cavalli,et al.  A Phase I Dose Escalation Study of Oxaliplatin, Cisplatin and Doxorubicin Applied as PIPAC in Patients with Peritoneal Carcinomatosis , 2021, Cancers.

[4]  B. Goh,et al.  PIPAC-OX: A Phase I Study of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy in Patients with Peritoneal Metastases , 2020, Clinical Cancer Research.

[5]  O. Sgarbura,et al.  Current practice of pressurized intraperitoneal aerosol chemotherapy (PIPAC): Still standardized or on the verge of diversification? , 2020, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[6]  A. Pisacane,et al.  Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Oxaliplatin, Cisplatin, and Doxorubicin in Patients with Peritoneal Carcinomatosis: An Open-Label, Single-Arm, Phase II Clinical Trial , 2020, Biomedicines.

[7]  L. Lundell,et al.  Pressurized intraperitoneal aerosol chemotherapy (PIPAC) of peritoneal metastasis from gastric cancer: a descriptive cohort study , 2020, Clinical & Experimental Metastasis.

[8]  E. Decullier,et al.  Pressurized intraperitoneal aerosol chemotherapy (PIPAC) might increase the risk of anastomotic leakage compared to HIPEC: an experimental study , 2019, Surgical Endoscopy.

[9]  M. Hübner,et al.  Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. , 2019, The Lancet. Oncology.

[10]  R. Cavalli,et al.  Exploring the Use of Pegylated Liposomal Doxorubicin (Caelyx®) as Pressurized Intraperitoneal Aerosol Chemotherapy , 2019, Front. Pharmacol..

[11]  C. Meisner,et al.  Pressurized intraperitoneal aerosol chemotherapy with low-dose cisplatin and doxorubicin (PIPAC C/D) in patients with gastric cancer and peritoneal metastasis: a phase II study , 2019, Therapeutic advances in medical oncology.

[12]  M. Pocard,et al.  Phase I/II study of oxaliplatin dose escalation via a laparoscopic approach using pressurized aerosol intraperitoneal chemotherapy (PIPOX trial) for nonresectable peritoneal metastases of digestive cancers (stomach, small bowel and colorectal): Rationale and design , 2018, Pleura and peritoneum.

[13]  C. Tempfer,et al.  How to Perform Safe and Technically Optimized Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC): Experience After a Consecutive Series of 1200 Procedures , 2018, Journal of Gastrointestinal Surgery.

[14]  C. Tempfer,et al.  A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis. , 2018, Gynecologic oncology.

[15]  C. Tempfer,et al.  Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal carcinomatosis: systematic review of clinical and experimental evidence with special emphasis on ovarian cancer , 2018, Archives of Gynecology and Obstetrics.

[16]  M. Pocard,et al.  Intraperitoneal aerosolization of albumin-stabilized paclitaxel nanoparticles (Abraxane™) for peritoneal carcinomatosis – a phase I first-in-human study , 2018, Pleura and peritoneum.

[17]  O. Sgarbura,et al.  Multicentric initial experience with the use of the pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the management of unresectable peritoneal carcinomatosis. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[18]  N. Demartines,et al.  Pressurized IntraPeritoneal Aerosol Chemotherapy - Practical aspects. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[19]  N. Demartines,et al.  Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis , 2017, The British journal of surgery.

[20]  M. Vaira,et al.  Single-port access for Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC): technique, feasibility and safety , 2016, Pleura and peritoneum.

[21]  V. Lemmens,et al.  Short-term outcome in patients treated with cytoreduction and HIPEC compared to conventional colon cancer surgery , 2016, Medicine.

[22]  M. Vaira,et al.  Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat peritoneal carcinomatosis , 2016, World Journal of Surgical Oncology.

[23]  W. Solass,et al.  Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis , 2016, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[24]  W. Solass,et al.  Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis , 2015, Journal of Gastrointestinal Surgery.

[25]  W. Solass,et al.  Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: A phase 2 study. , 2015, Gynecologic oncology.

[26]  Urs Giger-Pabst,et al.  Intraperitoneal Chemotherapy of Peritoneal Carcinomatosis Using Pressurized Aerosol as an Alternative to Liquid Solution: First Evidence for Efficacy , 2013, Annals of Surgical Oncology.

[27]  W. Solass,et al.  Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC): Occupational Health and Safety Aspects , 2013, Annals of Surgical Oncology.

[28]  F. Zoetmulder,et al.  Toxicity and mortality of cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei--a report of 103 procedures. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[29]  H. Tinteren,et al.  Toxicity of cytoreductive surgery and hyperthermic intra‐peritoneal chemotherapy , 2004, Journal of surgical oncology.